Carbenoxolone alters the morphology of adipose tissues and downregulates genes involved in adipogenesis, glucose transport and lipid metabolism in high-fat diet-fed mice

Hormone and Metabolic Research

Volumn 44, Issue 1, 2012, Pages 15-20

  Sano, S ^a   Nakagawa, Y ^a   Yamaguchi, R ^a   Fujisawa, Y ^a   Satake, E ^a   Nagata, E ^a   Nakanishi, T ^a   Liu, Y J ^b   Ohzeki, T ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

11 hydroxysteroid dehydrogenase type 1; adipogenesis; glucocorticoid; morphology; visceral fat

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; CARBENOXOLONE; CCAAT ENHANCER BINDING PROTEIN ALPHA; GLUCOSE TRANSPORTER 4; HORMONE SENSITIVE LIPASE; LIPOPROTEIN LIPASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL LIPASE;

ADIPOCYTE; ADIPOGENESIS; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL SIZE; CONTROLLED STUDY; GENE EXPRESSION; GENE REPRESSION; GENETIC REGULATION; GLUCOSE TRANSPORT; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIPID DIET; LIPID METABOLISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADIPOCYTES; ADIPOGENESIS; ADIPOSE TISSUE; ANIMALS; BIOLOGICAL TRANSPORT; BODY WEIGHT; CARBENOXOLONE; DIET, HIGH-FAT; DOWN-REGULATION; FEEDING BEHAVIOR; GLUCOSE; GLUCOSE TOLERANCE TEST; INSULIN; INTRA-ABDOMINAL FAT; LIPID METABOLISM; LIPOGENESIS; MALE; MICE; MICE, INBRED BALB C; ORGAN SIZE; RNA, MESSENGER;

MUS;

EID: 84855266973     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0031-1297990     Document Type: Article

References (35)

1. Kissebah A H, Vydelingum N, Murray R, Evans D J, Hartz A J, Kalkhoff R K, Adams P W. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab: 1982; 54 254 260 (Pubitemid 12006594)
2. Despres J P, Lemieux I, Prudhomme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ: 2001; 322 716 720 (Pubitemid 32238779)
3. Hautanen A, Raikkonen K, Adlercreutz H. Associations between pituitary-adrenocortical function and abdominal obesity, hyperinsulinaemia and dyslipidaemia in normotensive males. J Intern Med: 1997; 241 451 461 (Pubitemid 27315825)
4. Walker B R, Soderberg S, Lindahl B, Olsson T. Independent effects of obesity and cortisol in predicting cardiovascular risk factors in men and women. J Intern Med: 2000; 247 198 204 (Pubitemid 30108353)
5. Draper N, Stewart P M. 11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. J Endocrinol: 2005; 186 251 271 (Pubitemid 41167396)
6. Sjostrand M, Jansson P A, Sjogren L, Persson T, Eriksson J W. Repeated measurements of 11beta-HSD-1 activity in subcutaneous adipose tissue from lean, abdominally obese, and type 2 diabetes subjects no change following a mixed meal. Horm Metab Res: 2010; 42 798 802
7. Masuzaki H, Paterson J, Shinyama H, Morton N M, Mullins J J, Seckl J R, Flier J S. A transgenic model of visceral obesity and the metabolic syndrome. Science: 2001; 294 2166 2170 (Pubitemid 33150673)
8. Paterson J M, Morton N M, Fievet C, Kenyon C J, Holmes M C, Staels B, Seckl J R, Mulliuns J J. Metabolic syndrome without obesity: Hepatic overexpression of 11 beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci USA: 2004; 101 7088 7093 (Pubitemid 38596447)
9. Kotelevtsev Y, Holmes M C, Burchell A, Houston P M, Schmoll D, Jamieson P, Best R, Brown R, Edwards CR W, Seckl J R, Mullins J J. 11 beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA: 1997; 94 14924 14929 (Pubitemid 28041476)
10. Morton N M, Paterson J M, Masuzaki H, Holmes M C, Stales B, Fievet C, Walker B R, Flier J S, Mullins J J, Seckl J R. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes: 2004; 53 931 938 (Pubitemid 38436604)
11. Stimson R H, Andrew R, McAvoy N C, Tripathi D, Hayes P C, Walker B R. Increased whole-body and sustained liver cortisol regeneration by 11beta-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibition. Diabetes: 2011; 60 720 725
12. Ge R, Huang Y, Liang G, Li X. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development. Curr Med Chem: 2010; 17 412 422
13. Morton N M. Obesity and corticosteroids: 11 beta-Hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease. Molecular and Cellular Endocrinology: 2010; 316 154 164
14. Feig P U, Shah S, Hermanowski-Vosatka A, Plotkin D, Springer M S, Donahue S, Thach C, Klein E J, Lai E, Kaufman K D. Effects of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes Obes Metab: 2011; 13 498 504
15. Walker B R, Connacher A A, Lindsay R M, Webb D J, Edwards C R. Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab: 1995; 80 3155 3159
16. Andrews R C, Rooyackers O, Walker B R. Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab: 2003; 88 285 291 (Pubitemid 36115179)
17. Nuotio-Antar A M, Hachey D L, Hasty A H. Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice. Am J Physiol Endocrinol Metab: 2007; 293 E1517 E1528 (Pubitemid 350255101)
18. Liu Y, Nakagawa Y, Wang Y, Liu L, Du H, Wang W, Ren X, Lufty K, Friedman T C. Reduction of hepatic glucocorticoid receptor and hexose-6-phosphate dehydrogenase expression ameliorates diet-induced obesity and insulin resistance in mice. J Mol Endocrinol: 2008; 41 53 64
19. Taylor A, Irwin N, McKillop A M, Flatt P R, Gault V A. Sub-chronic administration of the 11 beta-HSD1 inhibitor, carbenoxolone, improves glucose tolerance and insulin sensitivity in mice with diet-induced obesity. Biol Chem: 2008; 389 441 445 (Pubitemid 351773918)
20. Weisberg S P, McCann D, Desai M, Rosenbaum M, Leibel R L, Ferrante A W. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest: 2003; 112 1796 1808 (Pubitemid 38063703)
21. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol: 2004; 25 4 7 (Pubitemid 38032801)
22. Jessen B A, Stevens G J. Expression profiling during adipocyte differentiation of 3T3-L1 fibroblasts. Gene: 2002; 299 95 100 (Pubitemid 35379830)
23. Bujalska I J, Gathercole L L, Tomlinson J W, Darimont C, Ermolieff J, Fanjul A N, Rejto P A, Stewart P M. A novel selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis. J Endocrinol: 2008; 197 297 307 (Pubitemid 351696242)
24. Wu Z, Rosen E D, Brun R, Hauser S, Adelmant G, Troy A E, Mckeon C, Darlington G J, Spiegelman B M. Cross-regulation of C/EBP alpha and PPAR gamma controls the transcriptional pathway of adipogenesis and insulin sensitivity. Mol Cell: 1999; 3 151 158 (Pubitemid 29292616)
25. Rosen E D, Sarraf P, Troy A E, Bradwin G, Moore K, Milstone D S, Spiegelman B M, Mortensen R M. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell: 1999; 4 611 617 (Pubitemid 29531140)
26. Liu Y, Park F, Pietrusz J L, Jia G, Singh R J, Netzel B C, Liang M. Suppression of 11beta-hydroxysteroid dehydrogenase type 1 with RNA interference substantially attenuates 3T3-L1 adipogenesis. Physiol Genomics: 2008; 32 343 351 (Pubitemid 351328557)
27. Aminova L R, Wilson B A. Calcineurin-independent inhibition of 3T3-L1 adipogenesis by Pasteurella multocida toxin: suppression of Notch1, stabilization of beta-catenin and pre-adipocyte factor 1. Cell Microbiol: 2007; 9 2485 2496 (Pubitemid 47365652)
28. Zechner R, Strauss J, Frank S, Wagner E, Hofmann W, Krakty D, Hiden M, Levak-Frank S. The role of lipoprotein lipase in adipose tissue development and metabolism. Int J Obes Relat Metab Disord: 2000; 24 04 S53 S56
29. Cho M C, Lee K, Paik S G, Yoon D Y. Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders. PPAR Res: 2008; 2008 679137
30. Fernyhough M E, Okine E, Hausman G, Vierck J L, Dodson M V. PPARgamma and GLUT-4 expression as developmental regulators/markers for preadipocyte differentiation into an adipocyte. Domest Anim Endocrinol: 2007; 33 367 378 (Pubitemid 47513814)
31. Monder C, Stewart P M, Lakshmi V, Valentino R, Burt D, Edwards C R. Licorice inhibits corticosteroid 11 beta-dehydrogenase of rat kidney and liver: in vivo and in vitro studies. Endocrinology: 1989; 125 1046 1053 (Pubitemid 19205104)
32. Gathercole L L, Stewart P M. Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes. J Steroid Biochem Mol Biol: 2010; 122 21 27
33. Yanagiya T, Tanabe A, Hotta K. Gap-junctional communication is required for mitotic clonal expansion during adipogenesis. Obesity (Silver Spring): 2007; 15 572 582 (Pubitemid 46643309)
34. Hollis G, Huber R. 11beta-Hydroxysteroid dehydrogenase type 1 inhibition in type 2 diabetes mellitus. Diabetes Obes Metab: 2011; 13 1 6
35. Rosenstock J, Banarer S, Fonseca V A, Inzucchi S E, Sun W, Yao W Q, Hollis G, Flores R, Levy R, Williams W V, Seckl J R, Huber R, Investigat I P. The 11-beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor INCB13739 Improves Hyperglycemia in Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy. Diabetes Care: 2010; 33 1516 1522